These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 32227504)
1. Letter: immunogenicity of infliximab-ready for routine prediction? Amiot A Aliment Pharmacol Ther; 2020 Apr; 51(8):812. PubMed ID: 32227504 [No Abstract] [Full Text] [Related]
2. Letter: immunogenicity of infliximab-ready for routine prediction? Authors' reply. Wilson A; Peel C; Wang Q; Pananos AD; Kim RB Aliment Pharmacol Ther; 2020 Apr; 51(8):813-814. PubMed ID: 32227506 [No Abstract] [Full Text] [Related]
3. Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator? Orfanoudaki E; Drygiannakis I; Koutroubakis IE Aliment Pharmacol Ther; 2018 Nov; 48(9):1037-1038. PubMed ID: 30318690 [No Abstract] [Full Text] [Related]
4. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. Fiorino G; Correale C; Radice S; Allocca M; Furfaro F; Gilardi D; Nagore D; Del Rio L; Pascual J; Martínez A; Danese S Aliment Pharmacol Ther; 2017 Nov; 46(9):903-905. PubMed ID: 29023889 [No Abstract] [Full Text] [Related]
5. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply. Komaki Y; Yamada A; Komaki F; Sakuraba A Aliment Pharmacol Ther; 2017 Nov; 46(9):905-906. PubMed ID: 29023885 [No Abstract] [Full Text] [Related]
6. Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab. Vegh Z; Kurti Z; Lakatos PL Dig Dis; 2017; 35(1-2):101-106. PubMed ID: 28147369 [TBL] [Abstract][Full Text] [Related]
7. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532 [TBL] [Abstract][Full Text] [Related]
8. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Katsanos KH; Papamichael K; Cheifetz AS; Christodoulou DK Inflamm Bowel Dis; 2018 Feb; 24(3):465-466. PubMed ID: 29462402 [No Abstract] [Full Text] [Related]
12. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. Martelli L; Peyrin-Biroulet L Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715 [TBL] [Abstract][Full Text] [Related]
13. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. Avila-Ribeiro P; Fiorino G; Danese S Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114 [TBL] [Abstract][Full Text] [Related]
19. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088 [TBL] [Abstract][Full Text] [Related]
20. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? Allocca M; Fiorino G; Danese S Dig Dis Sci; 2017 Nov; 62(11):2964-2965. PubMed ID: 28776140 [No Abstract] [Full Text] [Related] [Next] [New Search]